德展健康(000813.SZ)修正業績預告:2019年度淨利潤預降56.48%-70.98%
格隆匯3月30日丨德展健康(000813.SZ)發佈2019年度業績預告修正公告,前次業績預告,2019年度歸屬於上市公司股東的淨利潤為盈利2.1億元–3.15億元,同比下降66.15%-77.43%。
修正後,預計2019年度歸屬於上市公司股東的淨利潤2.7億元-4.05億元,同比下降56.48%-70.98%。
自2019年12起公司拓展了零售終端銷售渠道,因公司產品的良好療效得到了市場的認可,用藥人羣具有較高的忠誠度,阿樂產品在零售終端銷售情況良好;其次,在新冠狀病毒疫情期間,用藥人羣為減少外出次數,增加了在零售終端購買阿樂產品的數量。在上述兩項因素的影響下,原計劃退回至公司的阿樂產品數量顯著減少,導致公司原業績預告的淨利潤金額低於預期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.